Rosuvastatin protects against angiotensin II-induced renal injury in a dose-dependent fashion

Journal of Hypertension

Volumn 27, Issue 3, 2009, Pages 599-605

  Park, Joon Keun ^a   Mervaala, Eero M A ^b   Muller, Dominik N ^c   Menne, Jan ^a   Fiebeler, Anette ^a,c   Luft, Friedrich C ^c   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF HELSINKI   (Finland)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Angiotensin II; Cell adhesion; ICAM 1; Inflammation; INOS; Renal protection; Rosuvastatin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ANGIOTENSIN II; ANGIOTENSINOGEN; COLLAGEN; FIBRONECTIN; INTERCELLULAR ADHESION MOLECULE 1; RENIN; ROSUVASTATIN;

ALBUMINURIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTERIOLE; ARTICLE; BLOOD PRESSURE; CELL INFILTRATION; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; GENE; GLOMERULUS; HEART VENTRICLE HYPERTROPHY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY CORTEX; KIDNEY INJURY; KIDNEY MEDULLA; KIDNEY NECROSIS; LEUKOCYTE ADHERENCE; MONOCYTE; MORTALITY; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; RAT; RENAL PROTECTION; TRANSGENIC RAT;

EID: 67649547087     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/HJH.0b013e32831ef369     Document Type: Article

References (33)

1. Oda H, Keane WF. Recent advances in statins and the kidney. Kidney Int 1999; 56:S2-S5.
2. Kasiske BL, ÓDonnell MP, Garvis WL, Keane WF. Pharmacological treatment of hyperlipidemia reduces glomerular injury in rat 5/6 nephrectomy model of chronic renal failure. Circ Res 1988; 62:367-374.
3. ÓDonnell MP, Kasiske BL, Kim Y, Schmitz PG, Keane WF. Lovastatin retards the progression of established glomerular disease in obese Zucker rats. Am J Kidney Dis 1993; 22:83-89.
4. Harris KP, Purkerson ML, Yates J, Klahr S. Lovastatin ameliorates the development of glomerulosclerosis and uremia in experimental nephrotic syndrome. Am J Kidney Dis 1990; 15:16-23.
5. ParkJK, Muller DN, Mervaala EMA, Dechend R, Fiebeler A, Schmidt F, et al. Cerivastatin prevents angiotensin II-induced renal injury independent of blood pressure- and cholesterol-lowering effects. Kidney Int 2000; 58:1420-1430.
6. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, et al. Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 2001; 104:576-581.
7. Gueler F, Rong S, ParkJK, Fiebeler A, Menne J, Elger M, et al. Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 2002; 13:2288-2298.
8. Corsini A, Arnaboldi L, Raiteri M, Quarato P, Faggiotto A, Paoletti R, Fumagalli R. Effect of the new HMG-CoA reductase inhibitor cerivastatin (BAY W 6228) on migration, proliferation and cholesterol synthesis in arterial myocytes. Pharmacol Res 1996; 33:55-61.
9. Stalker TJ, Lefer AM, Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol 2001; 133:406-412.
10. Kleemann R, Princen HMG, Emeis JJ, Jukema JW, Fontijn RD, Horrevoets AJG, et al. Rosuvastatin reduces atherosclerosis development beyond and independent of its plasma cholesterol-lowering effect in APOEß3-Leiden transgenic mice. Circulation 2003; 108:1368-1374.
11. Kim S, Guijarro C, O'Donnell M, Kasiske B, Kim Y, Keane W. Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. Kidney Int 1995; 48:363-371.
12. Weber C, Erl W, Weber K, Weber P. Effects of oxidized low density lipoprotein, lipid mediators and statins on vascular cell interactions. Clin Chem Lab Med 1999; 37:243-251.
13. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J, Sanchez-Pascuala R, Hernandez G, Diaz C, Lamas S. Effects of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101:2711 -2719.
14. Luscher T, Tanner F, Noll G. Lipids and endothelial function: effect lipid-lowering and other therapeutic interventions. Curr Opin Lipidol 1996; 7:234-240.
15. Guijarro C, Kim Y, Schoonover C, Massy Z, O'Donnell M, Kasisk W, Kashtan C. Lovastatin inhibits lipopolysaccharide-induced NF-kappaB activation in human mesangial cells. Nephrol Dial Transplant 1996; 11:990-996.
16. O'Donnell M, Kasiske B, Kim Y, Atluru D, Keane W. The mevalonate pathway: importance in mesangial cell biology and glomerular disease. Miner Electrolyte Metab 1993; 19:173-179.
17. Bassa B, Roh D, Vazir N, Kirschenbaum M, Kamanna V. Effect of inhibition of cholesterol synthetic pathway on the activation of Ras and MAP kinase in mesangial cells. Biochim Biophys Acta 1999; 1449:137-149.
18. Muller DN, Dechend R, Mervaala EM, ParkJK, Schmidt F, Fiebeler A, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000; 35 (1 Pt 2):193-201.
19. Mervaala E, Müller DN, Schmidt F, ParkJK, Gross V, Bader M, et al. Blood pressure-independent effects in rats with human renin and angiotensinogen genes. Hypertension 2000; 35:587-594.
20. McTaggart F, Buckett L, Davidson R, Holdgate G, McCormick A, Schneck D, et al. Preclinical and clinical pharmacology of Rosuvastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. Am J Cardiol 2001; 87 (5A):28B-32B.
21. Theuer J, Shagdarsuren E, Muller DN, Kaergel E, Honeck H, Park JK, et al. Inducible NOS inhibition, eicosapentaenoic acid supplementation, and angiotensin II-induced renal damage. Kidney Int 2005; 67:248-258.
22. Pahan K, Sheikh FG, Namboodiri AM, Singh I. Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100:2671 -2679.
23. Muller DN, Shagdarsuren E, ParkJK, Dechend R, Mervaala E, Hampich F, et al. Immunosuppressive treatment protects against angiotensin II-induced renal damage. Am J Pathol 2002; 161:1679-1693.
24. Shagdarsuren E, Wellner M, Braesen JH, ParkJK, Fiebeler A, Henke N, et al. Complement activation in angiotensin II-induced organ damage. Circ Res 2005; 97:716-724.
25. Remuzzi G, Ruggenenti P. Prognosis of diabetic nephropathy: how to improve the outcome. Diabetes Res Clin Pract 1998; 39 (Suppl):S49-S53.
26. Whaley-Connell A, Habibi J, Nistala R, Cooper SA, Karuparthi PR, Hayden MR, et al. Attenuation of NADPH oxidase activation and glomerular filtration barrier remodeling with statin treatment. Hypertension 2008; 51:474-480.
27. Mervaala EM, Cheng ZJ, Tikkanen I, Lapatto R, Nurminen K, Vapaatalo H, et al. Endothelial dysfunction and xanthine oxidoreductase activity in rats with human renin and angiotensinogen genes. Hypertension 2001; 37 (2 Part 2):414-418.
28. Kourliouros A, De Souza A, Roberts N, Marciniak A, Tsiouris A, Valencia O, et al. Dose-related effect of statins on atrial fibrillation after cardiac surgery. Ann Thorac Surg 2008; 85:1515-1520.
29. Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14:1605-1613.
30. Guthrie RM, Martin DR. The safety of rosuvastatin: effects on renal and hepatic function. Expert Opin Drug Saf 2007; 6:573-581.
31. Kostapanos MS, Milionis HJ, Saougos VG, Lagos KG, Kostara C, Bairaktari ET, Elisaf MS. Dose-dependent effect of rosuvastatin treatment on urinary protein excretion. J Cardiovasc Pharmacol Ther 2007; 12:292-297.
32. Kraemer S, Kron S, Wang-Rosenke Y, Loof T, Khadzhynov D, Morgera S, et al. Rosuvastatin is additive to high-dose candesartan in slowing progression of experimental mesangio-proliferative glomerulosclerosis. Am J Physiol Renal Physiol 2008; 294:F801-F811.
33. Gianella A, Nobili E, Abbate M, Zoja C, Gelosa P, Mussoni L, et al. Rosuvastatin treatment prevents progressive kidney inflammation and fibrosis in stroke-prone rats. Am J Pathol 2007; 170:1165-1177.